<p>Various fractions of the population (0%, 30%, 50%, and 70%) from 2 to 14 years old or from 2 to 46 years old were pre-vaccinated and fifty simulations were run per scenario. The vaccine protects 70% of vaccinees against infection. The averages and standard deviations of the numbers of infections, symptomatic infections (cases of uncomplicated dengue fever), severe cases requiring hospitalization, and vaccinations per 100,000 individuals from fifty stochastic simulations per scenario are reported. Also reported are the average numbers of hospitalizations averted per 100,000 vaccinations.</p
BackgroundLarge Phase III trials across Asia and Latin America have recently demonstrated the effica...
<p><b>Background</b>: A case-cohort study, using a novel assay and data from three dengue vaccine ef...
Background Large Phase III trials across Asia and Latin America have recently demonstrated the effic...
<p>The yearly number of cases and hospitalizations per 100,000 individuals is estimated in 10-year s...
<p>Each plot shows the daily number of newly infected and symptomatic people from a single represent...
<p>The larger points represent the median attack rates (y-axis) of ten stochastic simulations run wh...
<p>Plotted are the average age-specific (A) infection incidence, (B) dengue fever incidence, and (C)...
Simulation pairs varied with respect to the proportion of vaccine efficacy due to protection from in...
and increasing urbanization. With no effective treatment and limited success of vector control, den...
and increasing urbanization. With no effective treatment and limited success of vector control, den...
With approximately 3 billion people at risk of acquiring the infection, dengue fever is now consider...
With approximately 3 billion people at risk of acquiring the infection, dengue fever is now consider...
Background: Dengue is a mosquito-borne infectious disease that constitutes a growing global threat w...
<div><p>Dengue vaccines will soon provide a new tool for reducing dengue disease, but the effectiven...
"accepted 16-Oct-2013"As the development of a dengue vaccine is ongoing, we simulate an hypothetical...
BackgroundLarge Phase III trials across Asia and Latin America have recently demonstrated the effica...
<p><b>Background</b>: A case-cohort study, using a novel assay and data from three dengue vaccine ef...
Background Large Phase III trials across Asia and Latin America have recently demonstrated the effic...
<p>The yearly number of cases and hospitalizations per 100,000 individuals is estimated in 10-year s...
<p>Each plot shows the daily number of newly infected and symptomatic people from a single represent...
<p>The larger points represent the median attack rates (y-axis) of ten stochastic simulations run wh...
<p>Plotted are the average age-specific (A) infection incidence, (B) dengue fever incidence, and (C)...
Simulation pairs varied with respect to the proportion of vaccine efficacy due to protection from in...
and increasing urbanization. With no effective treatment and limited success of vector control, den...
and increasing urbanization. With no effective treatment and limited success of vector control, den...
With approximately 3 billion people at risk of acquiring the infection, dengue fever is now consider...
With approximately 3 billion people at risk of acquiring the infection, dengue fever is now consider...
Background: Dengue is a mosquito-borne infectious disease that constitutes a growing global threat w...
<div><p>Dengue vaccines will soon provide a new tool for reducing dengue disease, but the effectiven...
"accepted 16-Oct-2013"As the development of a dengue vaccine is ongoing, we simulate an hypothetical...
BackgroundLarge Phase III trials across Asia and Latin America have recently demonstrated the effica...
<p><b>Background</b>: A case-cohort study, using a novel assay and data from three dengue vaccine ef...
Background Large Phase III trials across Asia and Latin America have recently demonstrated the effic...